AHCO
Q4 2026 EPS Estimate
$0.21
Nov 3, 2026 · Reports before open
Revenue Estimate
$726M
FY2027E EPS$0.12
FY2028E EPS$0.81

Analyst Sentiment

Wall St. Consensus
Buy
12 analysts·Moderate coverage
67
Score
9 Buy (75%)2 Hold (17%)1 Sell (8%)
Rating Breakdown
Strong Buy
00%
Buy
975%
Hold
217%
Sell
18%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$8.00
+53.3%
Consensus
$10.00
+91.6%
Bull
$13.00
+149.0%
12-Month Target Range12 analysts
$8.00$10.00$13.00
Current $5.22Consensus
Current Price
$5.22
Upside to Consensus
$4.78

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+3.70%
EPS
FY2028
Rev+8.40%
EPS+549.81%
FY2029
Rev+65.72%
EPS-40.71%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$2.96B$3.07B$3.32B$5.51B$6.29B
Low$2.76B$2.86B$2.75B$5.13B$5.86B
High$3.07B$3.19B$3.63B$5.73B$6.54B
EBITDA Avg$431M$447M$484M$803M$916M
Low$401M$416M$400M$748M$854M
High$448M$464M$529M$834M$952M
EBIT Avg$65M$67M$73M$121M$138M
Low$61M$63M$60M$113M$129M
High$68M$70M$80M$126M$144M
Net Income Avg$-3M$17M$112M$65M$88M
Low$-3M$15M$78M$59M$80M
High$-3M$18M$141M$68M$92M
EPS Avg$-0.02$0.12$0.81$0.48$0.65
Low$-0.03$0.11$0.58$0.44$0.59
High$-0.02$0.13$1.04$0.50$0.68
Analysts (Rev / EPS)4 / 14 / 23 / 21 / 12 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$768M$772M$767M$800M$811M$791M$726M$795M
Low$757M$762M$757M$789M$800M$780M$716M$785M
High$775M$779M$774M$808M$819M$798M$732M$803M
EBITDA Avg$112M$112M$112M$117M$118M$115M$106M$116M
Low$110M$111M$110M$115M$117M$114M$104M$114M
High$113M$114M$113M$118M$119M$116M$107M$117M
EBIT Avg$17M$17M$17M$18M$18M$17M$16M$17M
Low$17M$17M$17M$17M$18M$17M$16M$17M
High$17M$17M$17M$18M$18M$18M$16M$18M
Net Income Avg$12M$15M$-4M$8M$35M$33M$26M$29M
Low$12M$15M$-4M$8M$34M$33M$26M$28M
High$12M$15M$-4M$8M$35M$34M$27M$29M
EPS Avg$0.09$0.11$-0.03$0.06$0.26$0.24$0.19$0.21
Low$0.09$0.11$-0.03$0.06$0.25$0.24$0.19$0.21
High$0.09$0.11$-0.03$0.06$0.26$0.25$0.20$0.21
Analysts (Rev / EPS)4 / 34 / 32 / 12 / 12 / 12 / 11 / 21 / 2

Earnings Surprises

Recent Analyst Actions

Aug 6, 2026UBS
AdaptHealth price target lowered to $10 from $14 at UBS
Target:$10.00
+54.0%from $6.50
Aug 6, 2026RBC Capital
AdaptHealth price target lowered to $8 from $15 at RBC Capital
Target:$8.00
+23.2%from $6.50
Aug 5, 2026Truist Financial
AdaptHealth price target lowered to $9 from $14 at Truist
Target:$9.00
+38.4%from $6.50
Aug 5, 2026Robert W. Baird
AdaptHealth price target lowered to $10 from $15 at Baird
Target:$10.00
+49.0%from $6.71
Aug 5, 2026Canaccord Genuity
AdaptHealth price target lowered to $10 from $16 at Canaccord
Target:$10.00
+49.0%from $6.71
Jul 21, 2026Jefferies
Jefferies Upgrades AdaptHealth (AHCO) to Buy
Target:$13.00
+18.4%from $10.98
Jul 6, 2026Robert W. Baird
AdaptHealth price target lowered to $15 from $18 at Baird
Target:$15.00
+39.4%from $10.76
May 11, 2026RBC Capital
AdaptHealth price target raised to $15 from $13 at RBC Capital
Target:$15.00
+30.2%from $11.53
May 6, 2026Canaccord Genuity
AdaptHealth price target raised to $16 from $14 at Canaccord
Target:$16.00
+36.2%from $11.75
May 6, 2026Robert W. Baird
AdaptHealth price target raised to $18 from $17 at Baird
Target:$18.00
+53.2%from $11.75
Apr 20, 2026Jefferies
AdaptHealth price target raised to $11 from $9.50 at Jefferies
Target:$11.00
-13.6%from $12.73
Feb 26, 2026Leerink Partners
AdaptHealth (AHCO) PT Lowered to $12 at Leerink Partners
Target:$12.00
+28.6%from $9.33
Feb 25, 2026RBC Capital
RBC Capital on AdaptHealth (AHCO): 'Shares Appear Oversold Following Solid Guidance'
Target:$13.00
+45.9%from $8.91
Nov 15, 2024Truist Financial
AdaptHealth (AHCO) PT Lowered to $12 at Truist Securities
Target:$12.00
+22.4%from $9.80
Nov 6, 2024Robert W. Baird
AdaptHealth (AHCO) PT Lowered to $14 at Baird
Target:$14.00
+54.4%from $9.07
Sep 23, 2024Robert W. Baird
Baird Reiterates Outperform Rating on AdaptHealth (AHCO)
Target:$16.00
+40.1%from $11.42
Aug 8, 2024UBS
UBS Reiterates Buy Rating on AdaptHealth (AHCO)
Target:$13.00
+36.4%from $9.53
Sep 20, 2022Deutsche Bank
Deutsche Bank Maintains Buy on AdaptHealth, Raises Price Target to $28
Target:$28.00
+28.4%from $21.81
Sep 19, 2022Truist Financial
Truist Securities Maintains Buy on AdaptHealth, Raises Price Target to $28
Target:$28.00
+33.5%from $20.98
Aug 10, 2022RBC Capital
RBC Capital Maintains Outperform on AdaptHealth, Raises Price Target to $29
Target:$29.00
+30.4%from $22.24
Aug 10, 2022Leerink Partners
SVB Leerink Maintains Outperform on AdaptHealth, Raises Price Target to $29
Target:$29.00
+30.4%from $22.24
Jul 26, 2022Truist Financial
AdaptHealth (AHCO) Stock: $24 Target And Buy Rating
Target:$24.00
+14.3%from $21.00
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.